Results 171 to 180 of about 5,019 (231)

Format-tuning of in vivo-launched bispecific T cell engager enhances efficacy against renal cell carcinoma. [PDF]

J Immunother Cancer
O'Connell RP, Liaw K, Wellhausen N, Chuckran CA, Bhojnagarwala PS, Bordoloi D, Park D, Shupin N, Kulp D, June CH, Weiner D.   +10 more
europepmc   +1 more source

Targeted desialylation and cytolysis of tumour cells by fusing a sialidase to a bispecific T-cell engager. [PDF]

Nat Biomed Eng
Yang Z, Hou Y, Grande G, Cho JH, Wang C, Shi Y, Zak J, Wan Y, Qin K, Liu D, Teijaro JR, Lerner RA, Wu P.   +12 more
europepmc   +1 more source

Correspondence on 'Cardiovascular toxicities associated with bispecific T-cell engager therapy' by Sayed <i>et al</i>. [PDF]

J Immunother Cancer
Noguchi Y, Yan M, Tachi T, Yoshimura T.
europepmc   +1 more source

Response to: Correspondence on 'Cardiovascular toxicities associated with bispecific T-cell engager therapy' by Noguchi <i>et al</i>. [PDF]

J Immunother Cancer
Sayed A, Munir M, Poliner M, Sughra S, Epperla N, Addison D.   +5 more
europepmc   +1 more source

Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer. [PDF]

Cancer
Sands JM, Champiat S, Hummel HD, Paulson KG, Borghaei H, Alvarez JB, Carbone DP, Carlisle JW, Choudhury NJ, Clarke JM, Gadgeel SM, Izumi H, Navarro A, Lau SCM, Lammers PE, Huang S, Hamidi A, Mukherjee S, Owonikoko TK.   +18 more
europepmc   +1 more source

Targeting of acute myeloid leukemia by five-gene engineered T cells expressing transgenic T-cell receptor specific to WT1, chimeric antigenic receptor specific to GM-CSF receptor, bispecific T-cell engager specific to CD33, and tEGFR suicide gene system. [PDF]

Immunother Adv
Šmilauerová K, Štach M, Mucha M, Vaníková Š, Rychlá J, Otáhal P.   +5 more
europepmc   +1 more source

Immune-related adverse events with bispecific T-cell engager therapy targeting B-cell maturation antigen. [PDF]

Haematologica
Piron B, Bastien M, Antier C, Dalla-Torre R, Jamet B, Gastinne T, Dubruille V, Moreau P, Martin J, Bénichou A, Touzeau C, Tessoulin B.   +11 more
europepmc   +1 more source

Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells. [PDF]

J Immunother Cancer
Baugh R, Khalique H, Page E, Lei-Rossmann J, Wan PK, Johanssen T, Ebner D, Ansorge O, Seymour LW.   +8 more
europepmc   +1 more source

[The Chinese clinical expert consensus for the BCMA bispecific T cell engager in the treatment of multiple myeloma (2025)]. [PDF]

Zhonghua Xue Ye Xue Za Zhi
Chinese Hematology Association, Chinese Myeloma Committee, Plasma Cell Disease Group, Chinese Society of Hematology, Chinese Medical Association, Chinese Geriatrics Association, Society of Hematology.   +6 more
europepmc   +1 more source